New immunotherapy combo aims to stop head and neck cancer return
NCT ID NCT07379424
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests the immunotherapy drug sintilimab combined with radiotherapy in patients with resectable locally advanced head and neck cancer. Participants receive sintilimab before surgery, then again after surgery along with radiation. The study aims to see if this approach improves survival and prevents cancer from coming back. It will enroll 37 adults with certain types of head and neck cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab (an immunotherapy drug) combined with radiotherapy
- What this could lead to
- If successful, this could offer a new treatment approach to help prevent head and neck cancer from returning after surgery.
- What could go wrong
- This is a small, early-phase trial with only 37 participants, so results may not apply to everyone. Immunotherapy can cause side effects like inflammation in healthy organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China